O	0	1	[
O	1	10	Treatment
O	11	13	of
O	14	22	advanced
O	23	33	metastatic
O	34	40	breast
O	41	47	cancer
O	48	52	with
B-intervention	53	63	exemestane
O	63	64	,
O	65	66	a
O	67	78	multicenter
O	79	89	randomized
O	90	100	controlled
O	101	106	study
O	107	109	of
O	110	113	195
O	114	119	cases
O	119	120	]
O	120	121	.

O	122	124	To
O	125	132	observe
O	133	136	the
O	137	145	efficacy
O	146	148	of
O	149	159	exemestane
O	160	163	for
O	164	178	postmenopausal
O	179	187	advanced
O	188	198	metastatic
O	199	205	breast
O	206	212	cancer
O	212	213	,
O	214	217	and
O	218	220	to
O	221	227	assess
O	228	231	its
O	232	236	side
O	237	244	effects
O	244	245	.

O	246	247	A
O	248	258	randomized
O	258	259	,
O	260	266	double
O	266	267	-
O	267	272	blind
O	272	273	,
O	274	277	and
O	278	286	parallel
O	287	297	controlled
O	298	303	study
O	304	307	was
O	308	317	conducted
O	318	323	among
B-total-participants	324	327	195
B-eligibility	328	336	patients
I-eligibility	337	341	with
I-eligibility	342	356	postmenopausal
I-eligibility	357	365	advanced
I-eligibility	366	376	metastatic
I-eligibility	377	383	breast
I-eligibility	384	390	cancer
O	391	395	from
O	396	404	December
O	405	409	2001
O	410	412	to
O	413	417	June
O	418	422	2002
O	422	423	.

O	424	430	Except
O	431	434	for
O	435	438	the
O	439	440	4
O	441	446	cases
O	447	450	who
O	451	455	were
O	456	460	lost
O	461	463	to
O	464	470	follow
O	470	471	-
O	471	473	up
O	473	474	,
O	475	478	the
O	479	488	remaining
B-total-participants	489	492	191
O	493	501	patients
O	502	506	were
O	507	514	divided
O	515	519	into
O	520	523	two
O	524	530	groups
O	530	531	:
O	532	537	study
O	538	543	group
O	544	545	(
O	545	546	n
O	547	548	=
B-intervention-participants	549	551	96
O	551	552	,
O	553	560	treated
O	561	565	with
O	566	576	exemestane
O	577	584	capsule
O	585	587	25
O	588	590	mg
O	591	594	and
O	595	598	one
O	599	604	model
O	605	611	tablet
O	612	614	of
O	615	624	letrozole
O	625	631	orally
O	632	633	q
O	633	634	.
O	635	636	d
O	636	637	.
O	638	641	for
O	642	643	8
O	644	649	weeks
O	649	650	)
O	650	651	,
O	652	655	and
B-control	656	663	control
I-control	664	669	group
O	670	671	(
O	671	672	n
O	673	674	=
B-control-participants	675	677	95
O	677	678	,
O	679	686	treated
O	687	691	with
O	692	701	letrozole
O	702	703	2
O	703	704	.
O	704	705	5
O	706	708	mg
O	709	712	and
O	713	716	one
O	717	722	model
O	723	730	capsule
O	731	733	of
O	734	744	exemestane
O	745	751	orally
O	752	753	q
O	753	754	.
O	755	756	d
O	756	757	.
O	758	761	for
O	762	763	8
O	764	769	weeks
O	769	770	)
O	770	771	.

O	772	780	Physical
O	781	792	examination
O	792	793	,
O	794	809	roentgenography
O	810	813	and
O	814	816	CT
O	817	821	were
O	822	831	conducted
O	832	834	to
O	835	842	observe
O	843	846	the
O	847	854	outcome
O	855	857	of
O	858	861	the
O	862	867	tumor
O	868	871	and
O	872	875	the
O	876	881	level
O	882	884	of
O	885	893	estrogen
O	894	897	was
O	898	904	tested
O	905	906	2
O	907	912	weeks
O	913	919	before
O	920	923	and
O	924	925	4
O	926	929	and
O	930	931	8
O	932	937	weeks
O	938	943	after
O	944	947	the
O	948	957	beginning
O	958	960	of
O	961	970	treatment
O	970	971	.

O	972	975	The
B-outcome	976	985	effective
I-outcome	986	990	rate
O	991	994	was
B-iv-bin-percent	995	997	44
I-iv-bin-percent	997	998	.
I-iv-bin-percent	998	999	8
I-iv-bin-percent	999	1000	%
O	1001	1003	in
O	1004	1007	the
O	1008	1013	study
O	1014	1019	group
O	1020	1023	and
B-cv-bin-percent	1024	1026	45
I-cv-bin-percent	1026	1027	.
I-cv-bin-percent	1027	1028	3
I-cv-bin-percent	1028	1029	%
O	1030	1032	in
O	1033	1036	the
O	1037	1044	control
O	1045	1050	group
O	1051	1052	(
O	1052	1053	P
O	1054	1055	=
O	1056	1057	0
O	1057	1058	.
O	1058	1061	971
O	1061	1062	)
O	1062	1063	.

O	1064	1067	The
B-outcome	1068	1073	level
I-outcome	1074	1076	of
I-outcome	1077	1086	estradiol
O	1087	1090	was
B-iv-cont-mean	1091	1092	5
I-iv-cont-mean	1092	1093	.
I-iv-cont-mean	1093	1095	17
O	1096	1097	+
O	1097	1098	/
O	1098	1099	-
B-iv-cont-sd	1100	1101	6
I-iv-cont-sd	1101	1102	.
I-iv-cont-sd	1102	1104	68
I-iv-cont-sd	1105	1106	x
I-iv-cont-sd	1107	1109	10
I-iv-cont-sd	1109	1110	(
I-iv-cont-sd	1110	1111	4
I-iv-cont-sd	1111	1112	)
I-iv-cont-sd	1113	1115	pg
I-iv-cont-sd	1115	1116	/
I-iv-cont-sd	1116	1117	L
O	1118	1121	and
B-cv-cont-mean	1122	1123	4
I-cv-cont-mean	1123	1124	.
I-cv-cont-mean	1124	1126	19
O	1127	1128	+
O	1128	1129	/
O	1129	1130	-
B-cv-cont-sd	1131	1132	3
I-cv-cont-sd	1132	1133	.
I-cv-cont-sd	1133	1135	06
I-cv-cont-sd	1136	1137	x
I-cv-cont-sd	1138	1140	10
I-cv-cont-sd	1140	1141	(
I-cv-cont-sd	1141	1142	4
I-cv-cont-sd	1142	1143	)
I-cv-cont-sd	1144	1146	pg
I-cv-cont-sd	1146	1147	/
I-cv-cont-sd	1147	1148	L
O	1149	1151	in
O	1152	1155	the
O	1156	1161	study
O	1162	1167	group
O	1168	1171	and
O	1172	1179	control
O	1180	1185	group
O	1186	1198	respectively
O	1198	1199	;
O	1200	1203	and
O	1204	1207	was
B-iv-cont-mean	1208	1209	3
I-iv-cont-mean	1209	1210	.
I-iv-cont-mean	1210	1212	08
O	1213	1214	+
O	1214	1215	/
O	1215	1216	-
B-iv-cont-sd	1217	1218	2
I-iv-cont-sd	1218	1219	.
I-iv-cont-sd	1219	1221	80
I-iv-cont-sd	1222	1223	x
I-iv-cont-sd	1224	1226	10
I-iv-cont-sd	1226	1227	(
I-iv-cont-sd	1227	1228	4
I-iv-cont-sd	1228	1229	)
I-iv-cont-sd	1230	1232	pg
I-iv-cont-sd	1232	1233	/
I-iv-cont-sd	1233	1234	L
O	1235	1238	and
B-cv-cont-mean	1239	1240	2
I-cv-cont-mean	1240	1241	.
I-cv-cont-mean	1241	1243	76
O	1244	1245	+
O	1245	1246	/
O	1246	1247	-
B-cv-cont-sd	1248	1249	1
I-cv-cont-sd	1249	1250	.
I-cv-cont-sd	1250	1252	98
I-cv-cont-sd	1253	1254	x
I-cv-cont-sd	1255	1257	10
I-cv-cont-sd	1257	1258	(
I-cv-cont-sd	1258	1259	4
I-cv-cont-sd	1259	1260	)
I-cv-cont-sd	1261	1263	pg
I-cv-cont-sd	1263	1264	/
I-cv-cont-sd	1264	1265	L
O	1266	1268	in
O	1269	1272	the
O	1273	1278	study
O	1279	1284	group
O	1285	1288	and
O	1289	1296	control
O	1297	1302	group
O	1303	1315	respectively
O	1316	1317	8
O	1318	1323	weeks
O	1324	1329	after
O	1330	1333	the
O	1334	1343	beginning
O	1344	1346	of
O	1347	1356	treatment
O	1356	1357	,
O	1358	1362	both
O	1363	1372	decreased
O	1373	1375	by
O	1376	1378	43
O	1378	1379	.
O	1379	1380	7
O	1380	1381	%
O	1382	1384	in
O	1385	1395	comparison
O	1396	1400	with
O	1401	1406	those
O	1407	1413	before
O	1414	1423	treatment
O	1424	1425	(
O	1425	1429	both
O	1430	1431	P
O	1432	1433	<
O	1434	1435	0
O	1435	1436	.
O	1436	1439	001
O	1439	1440	)
O	1440	1441	,
O	1442	1449	however
O	1449	1450	,
O	1451	1456	there
O	1457	1460	was
O	1461	1463	no
O	1464	1475	significant
O	1476	1486	difference
O	1487	1494	between
O	1495	1498	the
O	1499	1504	study
O	1505	1510	group
O	1511	1514	and
O	1515	1522	control
O	1523	1528	group
O	1529	1530	(
O	1530	1531	P
O	1532	1533	=
O	1534	1535	0
O	1535	1536	.
O	1536	1539	141
O	1539	1540	)
O	1540	1541	.

O	1542	1545	The
O	1546	1550	side
O	1551	1558	effects
O	1559	1561	of
O	1562	1572	exemestane
O	1573	1581	included
B-outcome	1582	1588	thirst
O	1588	1589	,
B-outcome	1590	1599	giddiness
O	1599	1600	,
O	1601	1604	and
B-outcome	1605	1611	nausea
O	1611	1612	.

O	1613	1615	An
O	1616	1625	effective
O	1626	1634	hormonal
O	1635	1643	medicine
O	1643	1644	,
O	1645	1655	exemestane
O	1656	1659	has
O	1660	1664	good
O	1665	1676	therapeutic
O	1677	1685	efficacy
O	1686	1688	in
O	1689	1703	postmenopausal
O	1704	1712	advanced
O	1713	1723	metastatic
O	1724	1730	breast
O	1731	1737	cancer
O	1738	1742	with
O	1743	1747	only
O	1748	1752	mild
O	1753	1757	side
O	1758	1765	effects
O	1765	1766	.
